{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:47:15Z","timestamp":1778165235868,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SNSF 320030_204187"],"award-info":[{"award-number":["SNSF 320030_204187"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["323530_221874"],"award-info":[{"award-number":["323530_221874"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["PZ00P3_208670\/1"],"award-info":[{"award-number":["PZ00P3_208670\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Primary hyperparathyroidism (PHPT) often causes hypercalcemia and complications requiring parathyroidectomy (PTX). Anemia affects 15%-50% of PHPT patients, but its mechanisms remain unclear. While parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) contribute to anemia in secondary hyperparathyroidism through erythropoietin (EPO) resistance and bone marrow fibrosis, their roles in PHPT are less defined. This study explores the effect of PHPT on erythropoiesis by assessing hemoglobin (Hb), EPO, and FGF23 levels before and after PTX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a monocentric longitudinal study (2018-2020), PHPT patients scheduled for PTX were followed for 6 months. Blood and urine samples were collected at baseline (surgery day), at 10 days and 6 months postsurgery. Pearson correlation assessed relationships between Hb, EPO, PTH, FGF23, calcium, and phosphate at baseline and 6 months. Mixed-effects models evaluated the impact of PTH and FGF23 on Hb, adjusting for confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In a cohort of 111 PHPT patients (81% women, median age 64, normal body mass index), anemia prevalence decreased from 9.9% at baseline to 2.7% 6 months post-PTX, despite stable EPO levels. Postsurgery, PTH, FGF23, and calcium significantly decreased. PTH did not significantly correlate with Hb or EPO at any time point. Before surgery, FGF23 negatively correlated with Hb (R = \u22120.20, P = .020) and positively correlated with log-EPO (R = 0.38, P &amp;lt; .001). Mixed-effects models showed no predictive effect of PTH on Hb. However, multivariable models indicated a significant association between FGF23 and declining Hb (\u03b2 = \u2212.01, 95% confidence interval [\u22120.02; \u22120.01]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anemia in PHPT is linked to elevated FGF23 levels, potentially causing EPO resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf039","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:35:59Z","timestamp":1741714559000},"page":"290-298","source":"Crossref","is-referenced-by-count":5,"title":["Primary hyperparathyroidism induces erythropoietin resistance through fibroblast growth factor 23"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6640-1012","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Huber","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University Hospitals of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Demarchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Thoracic Surgery, University Hospitals of Geneva and Faculty of Medicine of the Geneva University , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-6315","authenticated-orcid":false,"given":"Thomas","family":"Verissimo","sequence":"additional","affiliation":[{"name":"Department of Cell Physiology, Faculty of Medicine, University of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marylise","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Cell Physiology, Faculty of Medicine, University of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dufey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University Hospitals of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Berchtold","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University Hospitals of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delal","family":"Dalga","sequence":"additional","affiliation":[{"name":"Department of Cell Physiology, Faculty of Medicine, University of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Triponez","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Thoracic Surgery, University Hospitals of Geneva and Faculty of Medicine of the Geneva University , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira M","family":"Sadowski","sequence":"additional","affiliation":[{"name":"Neuroendocrine Cancer Therapy Section, Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Ponte","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University Hospitals of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"de Seigneux","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology and Hypertension, University Hospitals of Geneva , 1205 Geneva ,","place":["Switzerland"]},{"name":"Department of Cell Physiology, Faculty of Medicine, University of Geneva , 1205 Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"2","key":"2025032107295829900_lvaf039-B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrendo.2017.104","article-title":"Primary hyperparathyroidism","volume":"14","author":"Walker","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2025032107295829900_lvaf039-B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporos Int"},{"issue":"10116","key":"2025032107295829900_lvaf039-B3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","article-title":"Hyperparathyroidism","volume":"391","author":"Bilezikian","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"2025032107295829900_lvaf039-B4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1365-2265.2008.03346.x","article-title":"Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy","volume":"70","author":"Bhadada","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2025032107295829900_lvaf039-B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/ijmr.IJMR_1200_19","article-title":"Haematological manifestations in primary hyperparathyroidism","volume":"155","author":"K\u0131r","year":"2022","journal-title":"Indian J Med Res"},{"issue":"4","key":"2025032107295829900_lvaf039-B6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.4103\/jfmpc.jfmpc_174_17","article-title":"Association of vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease","volume":"7","author":"Sonkar","year":"2018","journal-title":"J Fam Med Prim Care"},{"issue":"4","key":"2025032107295829900_lvaf039-B7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3892\/etm.2021.10593","article-title":"Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (review)","volume":"22","author":"Zhang","year":"2021","journal-title":"Exp Ther Med"},{"issue":"1","key":"2025032107295829900_lvaf039-B8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1023\/a:1021380609993","article-title":"Elderly patients on chronic hemodialysis: effect of the secondary hyperparathyroidism on the hemoglobin level","volume":"34","author":"Neves","year":"2002","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"2025032107295829900_lvaf039-B9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000044878","article-title":"Red blood cell osmotic fragility in chronically hemodialyzed patients","volume":"78","author":"Wu","year":"1998","journal-title":"Nephron"},{"issue":"761","key":"2025032107295829900_lvaf039-B10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/pgmj.65.761.136","article-title":"Parathyroid hormone and anaemia\u2013an erythrocyte osmotic fragility study in primary and secondary hyperparathyroidism","volume":"65","author":"Foulks","year":"1989","journal-title":"Postgrad Med J"},{"issue":"6","key":"2025032107295829900_lvaf039-B11","first-page":"9830","article-title":"Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"2025032107295829900_lvaf039-B12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1080\/0886022X.2021.1931318","article-title":"Effects of parathyroidectomy on plasma PTH fragments and heart rate variability in stage 5 chronic kidney disease patients","volume":"43","author":"Chen","year":"2021","journal-title":"Ren Fail"},{"issue":"6","key":"2025032107295829900_lvaf039-B13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11914-021-00703-w","article-title":"Regulation of FGF23: beyond bone","volume":"19","author":"Simic","year":"2021","journal-title":"Curr Osteoporos Rep"},{"issue":"17","key":"2025032107295829900_lvaf039-B14","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3390\/ijms20174195","article-title":"The role of fibroblast growth factor 23 in inflammation and anemia","volume":"20","author":"Czaya","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2025032107295829900_lvaf039-B15","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2215\/CJN.03950417","article-title":"Fibroblast growth factor 23 and anemia in the chronic renal insufficiency cohort study","volume":"12","author":"Mehta","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"2025032107295829900_lvaf039-B16","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1210\/clinem\/dgaa716","article-title":"Interactions of anemia, FGF-23, and bone in healthy adults-results from the study of health in pomerania (SHIP)","volume":"106","author":"Hannemann","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025032107295829900_lvaf039-B17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000485472","article-title":"Associations of fibroblast growth factor 23 with markers of inflammation and leukocyte transmigration in chronic kidney disease","volume":"138","author":"Wallquist","year":"2018","journal-title":"Nephron"},{"issue":"5","key":"2025032107295829900_lvaf039-B18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int"},{"issue":"5","key":"2025032107295829900_lvaf039-B19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1258\/000456307781646102","article-title":"The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays","volume":"44","author":"Durham","year":"2007","journal-title":"Ann Clin Biochem"},{"issue":"7","key":"2025032107295829900_lvaf039-B20","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1096\/fj.201700667R","article-title":"Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia","volume":"32","author":"Agoro","year":"2018","journal-title":"FASEB J"},{"issue":"1","key":"2025032107295829900_lvaf039-B21","doi-asserted-by":"publisher","first-page":"14989","DOI":"10.1038\/s41598-019-51577-z","article-title":"Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice","volume":"9","author":"Daryadel","year":"2019","journal-title":"Sci Rep"},{"issue":"14","key":"2025032107295829900_lvaf039-B22","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/jcm10143089","article-title":"Assessment of clinical utility of assaying FGF-23, klotho protein, osteocalcin, NTX, and sclerostin in patients with primary hyperparathyroidism","volume":"10","author":"Syka\u0142a","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"2025032107295829900_lvaf039-B23","doi-asserted-by":"publisher","first-page":"e210430","DOI":"10.1530\/EC-21-0430","article-title":"Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism","volume":"11","author":"Fo\u0159tov\u00e1","year":"2022","journal-title":"Endocr Connect"},{"key":"2025032107295829900_lvaf039-B24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/IJGM.S253246","article-title":"Evaluation of serum level of FGF23 and 1,25(OH)2D3 in primary hyperparathyroidism patients before and after parathyroidectomy","volume":"13","author":"Hassani","year":"2020","journal-title":"Int J Gen Med"},{"key":"2025032107295829900_lvaf039-B25","volume-title":"Guideline on Haemoglobin Cutoffs to Define Anaemia in Individuals and Populations","year":"2024"},{"issue":"3","key":"2025032107295829900_lvaf039-B26","doi-asserted-by":"publisher","first-page":"e92522","DOI":"10.1371\/journal.pone.0092522","article-title":"Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study","volume":"9","author":"Alwan","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2025032107295829900_lvaf039-B27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.kint.2016.04.024","article-title":"Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function","volume":"90","author":"Dhayat","year":"2016","journal-title":"Kidney Int"},{"issue":"14","key":"2025032107295829900_lvaf039-B28","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","article-title":"FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis","volume":"289","author":"Coe","year":"2014","journal-title":"J Biol Chem"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf039\/62377420\/lvaf039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/3\/290\/62377420\/lvaf039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/3\/290\/62377420\/lvaf039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:40:36Z","timestamp":1742704836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/192\/3\/290\/8069784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf039","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}